Georg Baron-Martiny
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Single-cell and spatial profiling reveal cDC2A-CXCL13+CD8+ T-epithelial cell crosstalk and cytotoxicity through TNFRSF9 in cutaneous and mucosal lichen planus.
Journal: Nature communications
Published: June 30, 2025
Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase Inhibitors.
Journal: Journal of medicinal chemistry
Published: August 10, 2016
A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis.
Journal: Journal of medicinal chemistry
Published: December 03, 2015
Podocyte EphB4 signaling helps recovery from glomerular injury.
Journal: Kidney international
Published: March 09, 2012
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
Journal: Molecular cancer therapeutics
Published: December 23, 2011
Targeting cancer with small-molecular-weight kinase inhibitors.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: October 01, 2011
The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.
Journal: Angiogenesis
Published: July 13, 2010
Showing 1-9 of 9
Last Updated: 09/26/2026